The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and radiofrequency ablation is safe for patients with lung tumors near central airways.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
17
3 fraction of stereotactic body radiation therapy within 10 days.
Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Achieve at most of 20% subacute or chronic grade 3 or higher lng, cardiac, or upper GI toxicity rate in patients treated with SBRT/RFA.
Time frame: 3 years
Achieve no more than 15% decline from the pre-treatment pulmonary function parameter (FEV1, DLCO) post-SBRT/RFA.
Time frame: 3 years
Achieve at least a 80% one-year local control (LC) rate by RECIST criterion or PET response (if applicable).
Time frame: 3 years
Progression-free survival
Time frame: 3 years
Overall survival
Time frame: 3 years
Concentration of serum TGF-B as early biomarker for treatment-inducted normal tissue injury
Time frame: 3 years
Concentration of serum VEGF as an early biomarker for response
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.